Member Info for Bella6532

Prelims 31 Dec 2021 - a reminder of what was said back then...

'If the AVA6000 Phase Ia study shows that the pre|CISION ™ chemistry is effective in reducing systemic

toxicity of doxorubicin in humans, then it can be applied to a wide range of other established

chemotherapies to potentially improve their safety and efficacy. This would be a significant value

inflection point during 2022 since it would open up a pipeline of proprietary, potentially safer, next

generation chemotherapies with significant clinical and commercial potential in a chemotherapy market

that is expected to grow to $56 billion by 2024.

The next most advanced pre|CISION™ pro-drug is AVA3996, a FAP-activated analogue of Velcade,

Takeda’s proteasome inhibitor. The global proteasome inhibitors’ market size is expected to be worth

$2.3 billion by 20261

, and Velcade represents just over half of that market. As with all chemotherapies,

the benefit of these drugs is limited by toxicities and tolerability for patients. In the case of Velcade,

there are significant side effects such as peripheral neuropathy which has limited its approval, principally

to multiple myeloma. A potentially safer proteasome inhibitor, such as AVA3996, could win significant

market share for the treatment not only of multiple myeloma but also could be used to treat solid

tumours, such as pancreatic cancer. Pancreatic cancer exhibits the highest level of FAP activity of any

solid tumour and therefore a FAPα-activated drug could have significant potential in this area of high

unmet need.

Shortly after the reporting period end, the Company announced that, following a review of efficacy

studies in several liquid and solid tumour models, safety studies and of manufacturability, AVA3996 has

been selected as a candidate for pre-clinical development with the aim of a Clinical Trial Authorisation

(‘CTA’) and/or Investigational New Drug (‘IND’) filing in the first half of 2023 and dosing of the first

patient later that year. '

Oh and going back to Takeda:

(Aug 2022) ‘Japanese major pharma Takeda ($44bn cap) has recently bought shares in Avacta'

AVA 3996, is an analogue protease inhibitor (bortezomib).

Takeda marketed Velcade, a branded version of bortezomib, in the US until Velcade's patent expired in 2022.

Avacta moved in literally next door to Takeda, in London.

Avacta has stated its intention - multiple times - to license out one of its preclinical prodrugs, in order to bring in some cash. AVA3996 is the most advanced...’

So if Avacta licence AVA3996 to Takeda this will potentially give Avacta the cash to take AVA6000 through to commercialisation by end 2026....

Oh and going back to Takeda:

(Aug 2022) ‘Japanese major pharma Takeda ($44bn cap) has recently bought shares in Avacta'

AVA 3996, is an analogue protease inhibitor (bortezomib).

Takeda marketed Velcade, a branded version of bortezomib, in the US until Velcade's patent expired in 2022.

Avacta moved in literally next door to Takeda, in London.

Avacta has stated its intention - multiple times - to license out one of its preclinical prodrugs, in order to bring in some cash. AVA3996 is the most advanced...’

So if Avacta licence AVA3996 to Takeda this will potentially give Avacta the cash to take AVA6000 through to commercialisation by end 2026....

Oh and going back to Takeda:

(Aug 2022) ‘Japanese major pharma Takeda ($44bn cap) has recently bought shares in Avacta'

AVA 3996, is an analogue protease inhibitor (bortezomib).

Takeda marketed Velcade, a branded version of bortezomib, in the US until Velcade's patent expired in 2022.

Avacta moved in literally next door to Takeda, in London.

Avacta has stated its intention - multiple times - to license out one of its preclinical prodrugs, in order to bring in some cash. AVA3996 is the most advanced...’

So if Avacta licence AVA3996 to Takeda this will potentially give Avacta the cash to take AVA6000 through to commercialisation by end 2026....

Now AS said this in the Interims...'In parallel, the Company will also initiate a fortnightly dosing safety study in order to determine the dosing regimen for a Phase 2 registrational study in soft tissue sarcoma planned to start during 2024, in advance of previous estimates. Subject to positive data, this could potentially bring the first pre|CISIONTM targeted chemotherapy to market for the benefit of patients with soft tissue sarcoma towards the end of 2026.'

So we have a timescale for full commercialisation of AVA6000 (to market for patients with STS). So who is going to finance all of this to get it to market...Avacta or Avacta/ANother?

They use the work potentially...is that to do with the data or finding a partner. Do they have a partner on the hook yet. Who really proposed a 2 weekly dosing study - Avacta or ANother? I thought Avacta wanted to keep AVA6000 for themselves and licence out the rest of the pipeline? Has this policy changed?

So many questions..

Rock on 13th....

Cont...

said so in a Y/E Results Presentation. Sometimes the answers are there but we don't always see them until after the fact.

JNJ has been mentioned...why?

I think we have the answers to many of the questions being asked but we are missing them or just not seeing them in the right context.

Hey ho...

Timster...I have never met Ophidian...we have simply met on another BB for a stock we were both invested in some time ago and shared our research openly on that BB. I don't always agree with his assessments and he doesn't always agree with mine but we and others on the BB managed to unearth lots of good stuff and through carefully reading between the lines of RNS's etc came up with the name of one of their M&A's before it was announced.

Baffyman...sorry I was referring to Eliots connection (F-star) who are a sub of a Chinese company.

'A British subsidiary of China’s Sino Biopharmaceutical has entered into a second licensing deal with Takeda Pharmaceutical. Japan’s largest drugmaker is expanding a collaboration with F-star Therapeutics, a UK and USA-based biotech which was bought by Sino’s UK-based business invoX Pharma in June 2022.'

https://www.thepharmaletter.com/article/takeda-doubles-down-on-f-star-s-dual-targeting-antibody-tech

Now the Bond resultied 'in gross cash proceeds of £52.25m due 2027 to a fund advised by Heights Capital Ireland LLC, a global equity and equity-linked focused investor'. HCI are registered as a one man band but I guess he's just a sub of the the much bigger company (US based ?).

and "This financing allows us to progress our M&A-led growth strategy for Avacta's diagnostics division and progress a pipeline of potential acquisitions in the European diagnostics sector to build a fully integrated and differentiated diagnostics business with global reach alongside the continued funding of Avacta's Therapeutics division to progress AVA6000 through the clinic and further develop the broader oncology pipeline."

I understand AS has since said there will be no more DX acquisitions so I guess the balance funds are now going to be used as stated on AVA6000 through the clinic and further develope the broader oncology pipeline. Note he said through clinic not through commercialisation.

I also understand AS has since said that we didn't need to worry about funding...so where and what additional funding might be required and when.

Sale of DX...Upfront payments...profits from income...partnership(s) etc etc...

Now this is what Dr Eliot Forster, Chairman of Avacta said in the Interims:

"Targeting of cancer therapies to tumour tissue has been a long sought after goal for many oncology drug companies, clinicians and patients. There are many potent anti-cancer drugs, the effectiveness of which is limited by the systemic toxicities and lack of tolerability for patients.

"The clinical data emerging for our lead pre|CISIONTM drug, AVA6000, is ground-breaking. We are seeing a dramatic reduction in the usual toxicities associated with anthracycline chemotherapy and we have clear indications that doxorubicin is being released in active form in the tumour microenvironment.

"Across the board we're proud and encouraged by the momentum we're seeing in both divisions of this business and see huge potential value both for patients and investors in the next period."

'There are many potent anti-cancer drugs, the effectiveness of which is limited by the systemic toxicities and lack of tolerability for patients.' AVA6000 is a key and not only will it unlock our pipeline, it will also unlock the use of other potent anti-cancer drugs. Now who might benefit most in this case??? Takeda are an obvious candidate for AVA3996 and Avacta have actually said

'Remember what I asked last week - who for and WHY ?'

I've been trying to pose the WHO question...

Then there's the WHY...

AVA6000 is an unlocking devise...so I've been thinking back on the lines of Takada for our next pipeline product. Didn't they hold some Avacta shares? Are they adding perhaps? Eliots connects would certainly be useful. Only thing I don't really like is the Chinese connection...but hey they are into everything anyway.

Finance going forward is not a problem - taken care of...again who and by what means.

JNJ...mmm! Don 't think they would be buying shares.

'There’s always a seller.'....and on the flip side...there's always a buyer...two sides to every coin...

HCI are making hands over fist with fees and selling on their shares at the prices gives them a massive return overall on thrir investment. They are more like loan sharks and just want to turn their loans ASAP. Rather than concentrate on them selling, surely more importantly is who is/are buying them. If a single buyer then that's either an ii or ? If more than one then we're getting more shareholders.

Hurst10...do you think a single entity is taking up a position or several?

06-Dec-23 16:11:29 135.00 15,000 Unknown* 20.25k O

06-Dec-23 16:11:21 135.00 15,000 Unknown* 20.25k O

05-Dec-23 08:44:44 135.215 20,000 Unknown* 27.04k O

05-Dec-23 15:13:34 134.00 82,500 Unknown* 110.55k O

05-Dec-23 08:44:39 135.215 20,000 Unknown* 27.04k O

05-Dec-23 11:11:46 134.15 25,000 Unknown* 33.54k O

05-Dec-23 14:06:15 133.825 40,000 Unknown* 53.53k O

05-Dec-23 16:20:50 135.00 124,258 Unknown* 167.75k O

06-Dec-23 17:05:24 134.50 5,602 Unknown* 7,535 O

06-Dec-23 14:40:38 135.40 15,000 Unknown* 20.31k O

06-Dec-23 16:40:24 135.00 160,000 Buy* 216.00k O

06-Dec-23 16:27:59 134.8432 12,778 Buy

There she blows...

Todays volumes:

627469 above mid (buys)

464089 below mid (sells)

568791 bang on mid (unknowns)

Total 1678349 volume

About 586,000 shares went through today as unknowns.

Thank you very much Estura. So the question is...

13th is a shareholder update as promised in Q4 and right now we don't know if the data will have been fully QC'd by then or not. If it has then we could see a push for MSM press coverage. If not fully QC'd then we will have to wait a little longer which could be end of 2 weeky dosing and full QCing thereafter...or am I still missing something...?

Hahaha...balancing the books eh?...don't think so...

04-Dec-23 08:22:13 136.75 25,000 Unknown* 34.19k O

04-Dec-23 08:22:21 136.75 25,000 Unknown* 34.19k O

04-Dec-23 15:39:39 134.85 20,000 Unknown* 26.97k O

04-Dec-23 08:13:40 136.50 25,000 Unknown* 34.13k O

04-Dec-23 08:13:47 136.50 25,000 Unknown* 34.13k O

04-Dec-23 08:03:43 135.50 20,000 Unknown* 27.10k O

04-Dec-23 15:44:55 134.85 20,000 Unknown* 26.97k O

04-Dec-23 16:07:16 134.75 20,000 Unknown* 26.95k O

04-Dec-23 08:03:47 135.50 20,000 Unknown* 27.10k O

05-Dec-23 17:10:36 133.00 17,259 Unknown* 22.95k O

05-Dec-23 14:46:00 135.00 15,000 Unknown* 20.25k O

05-Dec-23 14:45:55 135.00 15,000 Unknown* 20.25k O

05-Dec-23 16:37:40 135.00 24,206 Unknown* 32.68k O

05-Dec-23 16:35:12 133.00 89,138 Sell* 118.55k UT

05-Dec-23 16:29:47 134.7817 2,500 Sell* 3,370 O

05-Dec-23 16:28:45 135.00 3,700 Unknown* 4,995 O

05-Dec-23 16:25:34 134.70 363 Sell* 488.96 O

05-Dec-23 16:24:53 134.70 359 Sell* 483.57 O

05-Dec-23 16:23:41 134.70 2,969 Sell* 3,999 O

05-Dec-23 16:22:31 134.7817 7,341 Sell* 9,894 O

05-Dec-23 16:21:23 134.7817 4,094 Sell* 5,518 O

05-Dec-23 16:20:39 135.00 2,927 Unknown* 3,951 O

05-Dec-23 16:20:38 135.00 3,807 Unknown* 5,139 O

05-Dec-23 16:20:36 135.00 3,987 Unknown* 5,382 O

05-Dec-23 16:20:35 135.00 3,804 Unknown* 5,135 O

05-Dec-23 16:20:34 135.00 3,885 Unknown* 5,245 O

05-Dec-23 16:20:33 135.00 3,882 Unknown* 5,241 O

05-Dec-23 16:20:32 135.00 3,915 Unknown* 5,285 O

05-Dec-23 16:20:31 135.00 3,907 Unknown* 5,274 O

05-Dec-23 16:20:29 135.00 3,972 Unknown* 5,362 O

05-Dec-23 16:20:28 135.00 3,965 Unknown* 5,353 O

05-Dec-23 16:20:27 135.00 3,962 Unknown* 5,349 O

05-Dec-23 16:20:26 135.00 3,990 Unknown* 5,387 O

05-Dec-23 16:20:25 135.00 3,997 Unknown* 5,396 O

05-Dec-23 16:19:26 134.775 1,000 Buy* 1,348 O

05-Dec-23 16:18:47 134.755 15,000 Buy* 20.21k O

05-Dec-23 16:18:10 134.755 15,000 Buy* 20.21k O

05-Dec-23 16:15:57 134.7317 3,715 Buy* 5,005 O

05-Dec-23 16:15:50 134.725 302 Buy* 406.87 O

05-Dec-23 14:12:45 133.50 15,000 Unknown* 20.03k O

05-Dec-23 16:11:57 134.70 547 Buy* 736.81 O

05-Dec-23 16:11:37 134.70 733 Buy* 987.35 O

05-Dec-23 16:11:17 134.725 50 Buy* 67.36 O

05-Dec-23 16:08:05 135.00 7,809 Buy* 10.54k O

05-Dec-23 14:06:50 134.00 12,500 Unknown* 16.75k O

05-Dec-23 16:02:58 134.70 182 Buy* 245.15 O

05-Dec-23 16:02:36 134.70 2,350 Buy* 3,165 O

05-Dec-23 15:52:04 134.70 37 Buy* 49.84 O

05-Dec-23 15:47:33 134.80 3,034 Buy* 4,090 O

05-Dec-23 15:43:35 134.80 215 Buy* 289.82 O

05-Dec-23 15:42:05 134.80 1,477 Buy* 1,991 O

05-Dec-23 15:40:53 134.50 11,981 Unknown* 16.11k O

05-Dec-23 15:39:55 134.00004 175 Sell* 234.50 O

05-Dec-23 15:38:46 135.00 213 Buy* 287.55 O

05-Dec-23 15:37:38 135.00 14,948 Buy* 20.18k O

05-Dec-23 15:37:00 135.00 805 Buy* 1,087 O

05-Dec-23 15:33:15 135.00 262 Buy* 353.70 O

05-Dec-23 15:31:41 133.8567 754 Sell* 1,009 O

05-Dec-23 15:31:13 134.70 1,105 Buy* 1,488 O

05

Oops...the follow should have brdn addressed to Estura:

So the comments made by AS during your visit are what Myles M has based his X on re BBC and Sky etc.

MM said over the next couple of weeks, so did AS say the data would be released once QC'd?

Thanks for a tad more clarification

Beinthelead...I was not winding anyone up just trying to get some context to MMs X post. I apologise for my spelling too...mostly my haste as I have a rather hectic lifestyle but sometimes auto correct makes changes.